Standard or custom package
excellent quality and reliable supplier
*The following content is generated by AI and is for reference only.
Overview
Eculizumab is a recombinant humanized monoclonal antibody targeting complement protein C5. This therapeutic agent inhibits terminal complement activation to prevent hemolysis. Its standard molecular formula is C6892H10704N1832O2154S68 with CAS No. 219685-50-4.
Application
- Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults.
- Management of generalized Myasthenia Gravis (gMG) refractory to other therapies.
- Therapy for atypical Hemolytic Uremic Syndrome (aHUS).
- Prevention of thrombotic microangiopathy in high-risk kidney transplant recipients.
Precautions
Mandatory meningococcal vaccination is required prior to initiation due to infection risks. Store lyophilized powder at 2°C to 8°C; avoid freezing or shaking solutions. Strict aseptic techniques must be maintained during reconstitution and administration.